Finding an antibody with an attractive predicted binding score is only the start of discovery. Biopharmaceutical teams must establish whether a candidate can be produced, binds selectively and ...

Nucleus Network has recently opened its expanded facility in Sydney for Phase I clinical trials. Credit: Nucleus Network. There is no denying that Australia hits above its weight class in early ...

Moderna’s CEO Stéphane Bancel virtually attended the Financial Times Global Pharma and Biotech Summit on 10 November. Moderna’s mRNA-based vaccine intismeran in combination w ...

Delix Therapeutics has secured $100m in an oversubscribed Series C financing round to fund the development of Zalsupindole, an orally bioavailable neuroplastogen.

CRL has signed definitive agreements to acquire Frontage’s bioanalysis and DMPK operations in Exton, Pennsylvania for roughly $470m in cash.

Network Bio has entered into a research collaboration with Duke University to develop AI models of human disease using biospecimens and clinical records.

Alfasigma has received the EC's expanded approval for Jyseleca to treat adult patients living with active axial spondyloarthritis (axSpA).

The policy will allow licensed professionals to use certain wellness-focused peptides not approved by the FDA in their compounded medicines.

Through its PPIE initiative, the MHRA plans to consider a diverse range of patient and public opinions when making regulatory decisions.

The US Food and Drug Administration (FDA) has authorised Johnson & Johnson’s (J&J) Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) for certain patients with head and neck ...

Experts note that Democrats are likely to place Trump’s MFN deals under the microscope and vie to reverse sweeping Medicaid cuts following the midterm results.

Biotech investor Stephan Christgau speaks about the key considerations when devising a clinical strategy that will attract investor attention.